{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T05:51:27Z","timestamp":1781675487719,"version":"3.54.5"},"reference-count":140,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Type 2 diabetes mellitus (T2DM) significantly increases colorectal cancer (CRC) risk, driven by shared metabolic and inflammatory pathways. As lifelong glucose-lowering medications are routinely used in T2DM, their pharmacological activities and associated oncological effects have become critical for safety and repurposing. This review systematically summarizes the pharmacological mechanisms, epidemiological evidence, and clinical outcomes of eight antidiabetic drug classes in modulating CRC risk. We highlight drug-specific effects: metformin may act via AMPK\/mTOR and immune reprogramming; SGLT-2 inhibitors may exert direct cytotoxicity and indirect metabolic benefits; GLP-1 RAs show class-wide neutrality except high-dose semaglutide; DPP-4 inhibitors display dual pro- and anti-tumor effects; insulin and most secretagogues elevate CRC risk via hyperinsulinemia; while TZDs and AGIs offer modest chemopreventive effects. We conclude that antidiabetic drugs possess pharmacological properties that can inform CRC risk stratification and drug repurposing. Future research should prioritize mechanistic validation and precision pharmacology to translate these findings into clinical practice.<\/jats:p>","DOI":"10.3389\/fphar.2026.1849647","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:53:12Z","timestamp":1781671992000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacological mechanisms and clinical impacts of antidiabetic drugs on colorectal cancer risk: a systematic review"],"prefix":"10.3389","volume":"17","author":[{"given":"Yu","family":"Yang","sequence":"first","affiliation":[{"name":"The Second Hospital of Hebei Medical University","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kan","family":"Wang","sequence":"additional","affiliation":[{"name":"The Fourth Hospital of Hebei Medical University","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"140","DOI":"10.15430\/JCP.24.012","article-title":"Risk of incident cancer in veterans with diabetes who use metformin Versus sulfonylureas","volume":"29","author":"Abdallah","year":"2024","journal-title":"J. Cancer Prev."},{"key":"B2","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1097\/EDE.0000000000000793","article-title":"Incretin-based drugs and the incidence of colorectal cancer in patients with type 2 diabetes","volume":"29","author":"Abrahami","year":"2018","journal-title":"Epidemiology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"100667","DOI":"10.1016\/j.jgeb.2026.100667","article-title":"Genetic underpinnings of type-2 diabetes (T2D) with colorectal cancer (CRC): in-silico discovery of common molecular signatures, pathogenetic processes and therapeutic candidates","volume":"24","author":"Ahmmed","year":"2026","journal-title":"J. Genet. Eng. Biotechnol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e007235","DOI":"10.1136\/jitc-2023-007235","article-title":"Phase II trial of nivolumab and metformin in patients with treatment-refractory microsatellite stable metastatic colorectal cancer","volume":"11","author":"Akce","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2174\/011574888X283318240118111822","article-title":"Effect of pioglitazone and cetuximab on Colon cancer stem-like cell (CCSLCs) properties","volume":"20","author":"Alamdar","year":"2025","journal-title":"Curr. Stem Cell Res. Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"8334","DOI":"10.1002\/jcp.29677","article-title":"Metformin inhibition of colorectal cancer cell migration is associated with rebuilt adherens junctions and FAK downregulation","volume":"235","author":"Amable","year":"2020","journal-title":"J. Cell Physiol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"FC14","DOI":"10.7860\/JCDR\/2015\/16015.6979","article-title":"Evaluation of anti cancer effects of DPP-4 inhibitors in Colon Cancer- an invitro study","volume":"9","author":"Amritha","year":"2015","journal-title":"J. Clin. Diagn Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s11658-024-00599-1","article-title":"SGLT2 inhibitor promotes mitochondrial dysfunction and ER-phagy in colorectal cancer cells","volume":"29","author":"Anastasio","year":"2024","journal-title":"Cell Mol. Biol. Lett."},{"key":"B9","doi-asserted-by":"publisher","first-page":"8091","DOI":"10.1038\/s41598-021-87525-z","article-title":"Repositioning metformin and propranolol for colorectal and triple negative breast cancers treatment","volume":"11","author":"Anselmino","year":"2021","journal-title":"Sci. Rep."},{"key":"B10","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.biopha.2016.05.005","article-title":"Exenatide suppresses 1,2-dimethylhydrazine-induced colon cancer in diabetic mice: effect on tumor angiogenesis and cell proliferation","volume":"82","author":"awfik","year":"2016","journal-title":"Biomed. Pharmacother."},{"key":"B11","doi-asserted-by":"publisher","first-page":"538","DOI":"10.4143\/crt.2017.591","article-title":"Diabetes medication use in association with survival among patients of breast, colorectal, lung, or gastric cancer","volume":"51","author":"Baglia","year":"2019","journal-title":"Cancer Res. Treat."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e0334223","DOI":"10.1371\/journal.pone.0334223","article-title":"DPP4 inhibitors as a novel therapeutic strategy in colorectal cancer: integrating network biology and experimental insights","volume":"20","author":"Bardaweel","year":"2025","journal-title":"PLoS One"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1002\/cam4.2278","article-title":"Dipeptidyl peptidase 4 inhibitors as novel agents in improving survival in diabetic patients with colorectal cancer and lung cancer: a surveillance epidemiology and endpoint research medicare study","volume":"8","author":"Bishnoi","year":"2019","journal-title":"Cancer Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1634\/theoncologist.2012-0302","article-title":"Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis","volume":"18","author":"Bosetti","year":"2013","journal-title":"Oncologist"},{"key":"B15","doi-asserted-by":"publisher","first-page":"254","DOI":"10.2337\/diacare.29.02.06.dc05-1558","article-title":"Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin","volume":"29","author":"Bowker","year":"2006","journal-title":"Diabetes Care"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1038\/s41416-020-01208-6","article-title":"Metformin plus irinotecan in patients with refractory colorectal cancer: a phase 2 clinical trial","volume":"124","author":"Bragagnoli","year":"2021","journal-title":"Br. J. Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"101498","DOI":"10.1016\/j.molmet.2022.101498","article-title":"Metformin-induced reductions in tumor growth involves modulation of the gut microbiome","volume":"61","author":"Broadfield","year":"2022","journal-title":"Mol. Metab."},{"key":"B18","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/bcp.12350","article-title":"Insulin therapy and the risk of colorectal cancer in patients with type 2 diabetes: a meta-analysis of observational studies","volume":"78","author":"Bu","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e70490","DOI":"10.1002\/hsr2.70490","article-title":"Association between GLP1 RAs use and risk of colorectal cancer: a systematic review and meta-analysis","volume":"8","author":"Bushi","year":"2025","journal-title":"Health Sci. Rep."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.4103\/jcrt.jcrt_2670_22","article-title":"An AMPK agonist suppresses the progress of colorectal cancer by regulating the polarization of TAM to M1 through inhibition of HIF-1\u03b1 and mTOR signal pathway","volume":"19","author":"Cao","year":"2023","journal-title":"J. Cancer Res. Ther."},{"key":"B21","doi-asserted-by":"publisher","first-page":"E1170","DOI":"10.1210\/jc.2012-1162","article-title":"Oral insulin secretagogues, insulin, and cancer risk in type 2 diabetes mellitus","volume":"97","author":"Chang","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B22","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2337\/dc11-2197","article-title":"Use of thiazolidinediones and the risk of colorectal cancer in patients with diabetes: a nationwide, population-based, case-control study","volume":"36","author":"Chen","year":"2013","journal-title":"Diabetes Care"},{"key":"B23","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1093\/qjmed\/hcz253","article-title":"Insulin enhances and metformin reduces risk of colorectal carcinoma in type-2 diabetes","volume":"113","author":"Chen","year":"2020","journal-title":"QJM"},{"key":"B24","doi-asserted-by":"publisher","first-page":"11844","DOI":"10.1038\/s41598-023-38431-z","article-title":"Diabetes medications and cancer risk associations: a systematic review and meta-analysis of evidence over the past 10 years","volume":"13","author":"Chen","year":"2023","journal-title":"Sci. Rep."},{"key":"B25","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12885-025-13452-1","article-title":"Causality between insulin use and malignant tumors of the digestive system: a two-sample Mendelian randomized study","volume":"25","author":"Chen","year":"2025","journal-title":"BMC Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1111\/jgh.16498","article-title":"The impact of sodium-glucose cotransporter-2 inhibitors on outcome of patients with diabetes mellitus and colorectal cancer","volume":"39","author":"Chiang","year":"2024","journal-title":"J. Gastroenterol. Hepatol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"840142","DOI":"10.3389\/fonc.2022.840142","article-title":"Association between DPP-4 inhibitors and events of colorectal and liver cancers in patients with diabetes receiving second-line agents: a nested case-control study","volume":"12","author":"Chou","year":"2022","journal-title":"Front. Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ejca.2022.02.005","article-title":"Impact of diabetes and metformin use on recurrence and outcome in stage II-III colon cancer patients-A pooled analysis of three adjuvant trials","volume":"166","author":"Christou","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e2137","DOI":"10.1002\/biof.2137","article-title":"Suppression of colorectal cancer growth: interplay between curcumin and metformin through DMT1 downregulation and ROS-mediated pathways","volume":"51","author":"Chuang","year":"2025","journal-title":"Biofactors"},{"key":"B30","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s10350-007-9184-1","article-title":"Insulin therapy and colorectal adenoma risk among patients with type 2 diabetes mellitus: a case-control study in Korea","volume":"51","author":"Chung","year":"2008","journal-title":"Dis. Colon Rectum"},{"key":"B31","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.diabet.2012.08.011","article-title":"Insulin use and cancer risk in patients with type 2 diabetes: a systematic review and meta-analysis of observational studies","volume":"38","author":"Colmers","year":"2012","journal-title":"Diabetes Metab."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1007\/s00125-009-1440-6","article-title":"The influence of glucose-lowering therapies on cancer risk in type 2 diabetes","volume":"52","author":"Currie","year":"2009","journal-title":"Diabetologia"},{"key":"B33","doi-asserted-by":"publisher","first-page":"85","DOI":"10.5114\/wo.2024.142553","article-title":"Metformin in the treatment of colorectal cancer and neuroendocrine tumours","volume":"28","author":"Dani\u0142owska","year":"2024","journal-title":"Contemp. Oncol. (Pozn)"},{"key":"B34","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s00592-020-01479-8","article-title":"Risk of cancer in patients treated with dipeptidyl peptidase-4 inhibitors: an extensive meta-analysis of randomized controlled trials","volume":"57","author":"Dicembrini","year":"2020","journal-title":"Acta Diabetol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1097\/EDE.0000000000001626","article-title":"Evaluating metformin strategies for cancer prevention: a target trial emulation using electronic health records","volume":"34","author":"Dickerman","year":"2023","journal-title":"Epidemiology"},{"key":"B36","doi-asserted-by":"publisher","first-page":"115299","DOI":"10.1016\/j.intimp.2025.115299","article-title":"Metformin inhibits NF-\u03baB p65\/RelA-NLRP3 inflammasome-IL-1\u03b2 axis, attenuates lipid droplet accumulation, and reprograms CD14\/CD16 expression in monocytes exposed to colorectal tumor-conditioned medium","volume":"164","author":"Djebri","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.21873\/invivo.14032","article-title":"The effect of metformin usage in patients with metastatic colorectal cancer receiving first-line systemic therapy","volume":"39","author":"Erdat","year":"2025","journal-title":"In Vivo"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.3390\/biom12091301","article-title":"The association of metformin, other antidiabetic medications and statins on the prognosis of rectal cancer in patients with type 2 diabetes: a retrospective cohort study","volume":"12","author":"Erkinantti","year":"","journal-title":"Biomolecules"},{"key":"B39","doi-asserted-by":"publisher","first-page":"10732748221134090","DOI":"10.1177\/10732748221134090","article-title":"The Association of Metformin, other antidiabetic medications, and statins with the prognosis of Colon cancer in patients with type 2 diabetes: a retrospective cohort study","volume":"29","author":"Erkinantti","year":"","journal-title":"Cancer control."},{"key":"B40","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1002\/biof.1947","article-title":"Metformin and thymoquinone co-treatment enhance 5-fluorouracil cytotoxicity by suppressing the PI3K\/mTOR\/HIF1\u03b1 pathway and increasing oxidative stress in colon cancer cells","volume":"49","author":"Farrash","year":"2023","journal-title":"Biofactors"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1002\/ijc.28260","article-title":"Long-term treatment with Sitagliptin, a dipeptidyl peptidase-4 inhibitor, reduces colon carcinogenesis and reactive oxygen species in 1,2-dimethylhydrazine-induced rats","volume":"133","author":"Femia","year":"2013","journal-title":"Int. J. Cancer"},{"key":"B42","doi-asserted-by":"publisher","first-page":"108755","DOI":"10.1016\/j.diabres.2021.108755","article-title":"Metformin and cancer-specific survival among breast, colorectal, or endometrial cancer patients: a nationwide data linkage study","volume":"175","author":"Feng","year":"2021","journal-title":"Diabetes Res. Clin. Pract."},{"key":"B43","doi-asserted-by":"publisher","first-page":"107401","DOI":"10.1016\/j.phrs.2024.107401","article-title":"Glucagon-like peptide-1 receptor agonists and risk of gastrointestinal cancers: a systematic review and meta-analysis of randomized controlled trials","volume":"208","author":"Figlioli","year":"2024","journal-title":"Pharmacol. Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"20420986251318842","DOI":"10.1177\/20420986251318842","article-title":"Impact of dipeptidyl peptidase-4 inhibitors on incidence of colorectal cancer in patients with type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"16","author":"Fu","year":"2025","journal-title":"Ther. Adv. Drug Saf."},{"key":"B45","doi-asserted-by":"publisher","first-page":"4355","DOI":"10.3892\/ol.2017.6698","article-title":"Sitagliptin, a dipeptidyl peptidase-4 inhibitor, suppresses CXCL5 and SDF-1 and does not accelerate intestinal neoplasia formation in ApcMin\/+ mice fed a high-fat diet","volume":"14","author":"Fujiwara","year":"2017","journal-title":"Oncol. Lett."},{"key":"B46","doi-asserted-by":"publisher","first-page":"18456","DOI":"10.18632\/oncotarget.14472","article-title":"Diabetes cancer connect consortium. 2017 update on the relationship between diabetes and colorectal cancer: epidemiology, potential molecular mechanisms and therapeutic implications","volume":"8","author":"Gonz\u00e1lez","year":"2017","journal-title":"Oncotarget"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1200\/JCO.2006.07.2777","article-title":"Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes","volume":"25","author":"Govindarajan","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"3953","DOI":"10.2337\/dc13-0140","article-title":"Cohort study of insulin glargine and risk of breast, prostate, and colorectal cancer among patients with diabetes","volume":"36","author":"Habel","year":"2013","journal-title":"Diabetes Care"},{"key":"B49","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1186\/s13098-025-01898-z","article-title":"Comparative risk of cancer associated with SGLT inhibitors and DPP-4 inhibitors in patients with diabetes: a systematic review and meta-analysis","volume":"17","author":"Hajishah","year":"2025","journal-title":"Diabetol. Metab. Syndr."},{"key":"B50","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3390\/ph17030299","article-title":"Implications of NLRP3 suppression using glibenclamide and miR-223 against colorectal cancer","volume":"17","author":"Hamza","year":"2024","journal-title":"Pharm. (Basel)"},{"key":"B51","doi-asserted-by":"publisher","first-page":"97862","DOI":"10.18632\/oncotarget.18416","article-title":"Alpha-glucosidase inhibitor use is associated with decreased colorectal neoplasia risk in patients with type 2 diabetes mellitus receiving colonoscopy: a retrospective study","volume":"8","author":"Horibe","year":"2017","journal-title":"Oncotarget"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1007\/s00228-016-2068-3","article-title":"Effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors on colorectal cancer incidence and its precursors","volume":"72","author":"Htoo","year":"2016","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"103037","DOI":"10.1016\/j.ebiom.2020.103037","article-title":"Metformin elicits antitumour effect by modulation of the gut microbiota and rescues Fusobacterium nucleatum-induced colorectal tumourigenesis","volume":"61","author":"Huang","year":"2020","journal-title":"EBioMedicine"},{"key":"B54","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1158\/0008-5472.CAN-22-3042","article-title":"Metformin reprograms tryptophan metabolism to stimulate CD8+ T-cell function in colorectal cancer","volume":"83","author":"Huang","year":"","journal-title":"Cancer Res."},{"key":"B55","doi-asserted-by":"publisher","first-page":"e2221653120","DOI":"10.1073\/pnas.2221653120","article-title":"Nuclear VCP drives colorectal cancer progression by promoting fatty acid oxidation","volume":"120","author":"Huang","year":"","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1093\/jnci\/djaf165","article-title":"Metformin use and risk of colorectal cancer in patients with inflammatory bowel disease: a nationwide, population-based cohort study","volume":"117","author":"Huang","year":"2025","journal-title":"J. Natl. Cancer Inst."},{"key":"B57","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1097\/JS9.0000000000003450","article-title":"The different colorectal tumor risk related to GLP-1 receptor agonists and SGLT2 inhibitors use: a network meta-analysis of 68 randomized controlled trials","volume":"112","author":"Hung","year":"2025","journal-title":"Int. J. Surg."},{"key":"B58","doi-asserted-by":"publisher","first-page":"4454","DOI":"10.1111\/dom.70090","article-title":"Weight loss interventions and obesity-associated cancers in people with type 2 diabetes and overweight\/obesity: a real-world observational study","volume":"27","author":"Ipaye","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"B59","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s12672-012-0112-z","article-title":"Systematic review and meta-analysis of insulin therapy and risk of cancer","volume":"3","author":"Janghorbani","year":"2012","journal-title":"Horm. Cancer"},{"key":"B60","doi-asserted-by":"publisher","first-page":"175749","DOI":"10.1016\/j.ejphar.2023.175749","article-title":"PPAR\u03b3 agonist pioglitazone enhances colorectal cancer immunotherapy by inducing PD-L1 autophagic degradation","volume":"950","author":"Jia","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13098-024-01359-z","article-title":"The causal relationship between anti-diabetic drugs and gastrointestinal disorders: a drug-targeted mendelian randomization study","volume":"16","author":"Ju","year":"2024","journal-title":"Diabetol. Metab. Syndr."},{"key":"B62","doi-asserted-by":"publisher","first-page":"333","DOI":"10.2174\/15680266113136660067","article-title":"Use of insulin and insulin analogs and risk of cancer - systematic review and meta-analysis of observational studies","volume":"8","author":"Karlstad","year":"2013","journal-title":"Curr. Drug Saf."},{"key":"B63","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.3892\/or.2019.7357","article-title":"Suppressive effects of the sodiumglucose cotransporter 2 inhibitor tofogliflozin on colorectal tumorigenesis in diabetic and obese mice","volume":"42","author":"Kato","year":"2019","journal-title":"Oncol. Rep."},{"key":"B64","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.3390\/ijms21062226","article-title":"Alpha-Glucosidase inhibitor voglibose suppresses azoxymethane-induced colonic preneoplastic lesions in diabetic and Obese mice","volume":"21","author":"Kato","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B65","doi-asserted-by":"publisher","first-page":"6658","DOI":"10.1038\/s41598-025-91022-y","article-title":"Metformin modulates FJX1 via upregulation of Hsa-miR-1306-3p to suppress colon adenocarcinoma viability","volume":"15","author":"Kim","year":"2025","journal-title":"Sci. Rep."},{"key":"B66","doi-asserted-by":"publisher","first-page":"3362","DOI":"10.1210\/en.2011-1201","article-title":"Glucagon-like peptide-1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells","volume":"152","author":"Koehler","year":"2011","journal-title":"Endocrinology"},{"key":"B67","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/j.1349-7006.2001.tb01108.x","article-title":"Troglitazone, a ligand for peroxisome proliferator-activated receptor gamma, inhibits chemically-induced aberrant crypt foci in rats","volume":"92","author":"Kohno","year":"2001","journal-title":"Jpn. J. Cancer Res."},{"key":"B68","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1002\/pds.1352","article-title":"Cancer risks in thiazolidinedione users compared to other anti-diabetic agents","volume":"16","author":"Koro","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1007\/s00125-025-06453-z","article-title":"Glucagon-like peptide-1 receptor agonists and gastrointestinal cancer risk in individuals with type 2 diabetes","volume":"68","author":"Kuo","year":"2025","journal-title":"Diabetologia"},{"key":"B70","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s12957-023-03087-6","article-title":"Metformin increases pathological responses to rectal cancers with neoadjuvant chemoradiotherapy: a systematic review and meta-analysis","volume":"21","author":"Lai","year":"2023","journal-title":"World J. Surg. Oncol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"113683","DOI":"10.1016\/j.intimp.2024.113683","article-title":"Metformin alleviates colitis-associated colorectal cancer via inhibition of the TLR4\/MyD88\/NF\u03baB\/MAPK pathway and macrophage M2 polarization","volume":"144","author":"Lai","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1007\/s10620-024-08350-8","article-title":"Exogenous insulin therapy is associated with the risk of advanced colorectal adenoma in patients with diabetes mellitus","volume":"69","author":"Lam","year":"2024","journal-title":"Dig. Dis. Sci."},{"key":"B73","doi-asserted-by":"publisher","first-page":"36850419886448","DOI":"10.1177\/0036850419886448","article-title":"Rosiglitazone enhances the apoptotic effect of 5-fluorouracil in colorectal cancer cells with high-glucose-induced glutathione","volume":"103","author":"Lau","year":"2020","journal-title":"Sci. Prog."},{"key":"B74","doi-asserted-by":"publisher","first-page":"119873","DOI":"10.1016\/j.bbamcr.2024.119873","article-title":"Metformin induces apoptosis in TRAIL-resistant colorectal cancer cells","volume":"1872","author":"Lee","year":"2025","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1053\/j.gastro.2008.09.004","article-title":"Thiazolidinedione therapy is not associated with increased colonic neoplasia risk in patients with diabetes mellitus","volume":"135","author":"Lewis","year":"2008","journal-title":"Gastroenterology"},{"key":"B76","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1080\/13543784.2022.2113056","article-title":"Dipeptidyl peptidase 4-inhibitor treatment was associated with a reduced incidence of neoplasm in patients with type 2 diabetes: a meta-analysis of 115 randomized controlled trials with 121961 participants","volume":"31","author":"Li","year":"2022","journal-title":"Expert Opin. Investig. Drugs"},{"key":"B77","doi-asserted-by":"publisher","first-page":"e2400845","DOI":"10.1002\/advs.202400845","article-title":"Mitochondria-modulating liposomes reverse radio-resistance for colorectal cancer","volume":"11","author":"Li","year":"","journal-title":"Adv. Sci. (Weinh)"},{"key":"B78","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s10620-023-08211-w","article-title":"Gliclazide reduces colitis-associated colorectal cancer formation by deceasing colonic inflammation and regulating AMPK-NF-\u03baB signaling pathway","volume":"69","author":"Li","year":"","journal-title":"Dig. Dis. Sci."},{"key":"B79","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s12672-025-03223-6","article-title":"Liraglutide inhibits the development of colorectal cancer by regulating TGF-\u03b2\/Smad3 signaling pathway and affecting epithelial-mesenchymal transition","volume":"16","author":"Li","year":"2025","journal-title":"Discov. Oncol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1051\/bmdcn\/2019090104","article-title":"Association between colorectal cancer and thiazolidinediones administration in a case-control study","volume":"9","author":"Liao","year":"2019","journal-title":"Biomed. (Taipei)"},{"key":"B81","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/jcpt.12151","article-title":"Dose effect of thiazolidinedione on cancer risk in type 2 diabetes mellitus patients: a six-year population-based cohort study","volume":"39","author":"Lin","year":"2014","journal-title":"J. Clin. Pharm. Ther."},{"key":"B82","doi-asserted-by":"publisher","first-page":"75","DOI":"10.4103\/sjg.SJG_295_17","article-title":"Thiazolidinediones and risk of colorectal cancer in patients with diabetes mellitus: a meta-analysis","volume":"24","author":"Liu","year":"2018","journal-title":"Saudi J. Gastroenterol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2174\/0115748928274081240201060643","article-title":"Metformin inhibits NLRP3 inflammasome expression and regulates inflammatory microenvironment to delay the progression of colorectal cancer","volume":"20","author":"Liu","year":"2025","journal-title":"Recent Pat. Anticancer Drug Discov."},{"key":"B84","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1186\/s12916-023-03034-y","article-title":"Establishment of a large-scale patient-derived high-risk colorectal adenoma organoid biobank for high-throughput and high-content drug screening","volume":"21","author":"Luo","year":"2023","journal-title":"BMC Med."},{"key":"B85","doi-asserted-by":"publisher","first-page":"11640","DOI":"10.3390\/ijms252111640","article-title":"Glyburide suppresses inflammation-related colorectal tumorigenesis through inhibition of NLRP3 inflammasome","volume":"25","author":"Maeda","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B86","doi-asserted-by":"publisher","first-page":"e70206","DOI":"10.1002\/jbt.70206","article-title":"Linagliptin mitigates DMH-induced colorectal cancer in rats: crosstalk between NFAT and IL-6\/JAK2\/STAT3\/NF-\u03baB signaling hubs","volume":"39","author":"Mahmoud","year":"2025","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1136\/gutjnl-2023-331701","article-title":"Optimal glycaemic control and the reduced risk of colorectal adenoma and cancer in patients with diabetes: a population-based cohort study","volume":"73","author":"Mao","year":"2024","journal-title":"Gut"},{"key":"B88","doi-asserted-by":"publisher","first-page":"7263","DOI":"10.3748\/wjg.v12.i45.7263","article-title":"Effect of ligand troglitazone on peroxisome proliferator-activated receptor gamma expression and cellular growth in human colon cancer cells","volume":"12","author":"Ming","year":"2006","journal-title":"World J. Gastroenterol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"11395","DOI":"10.3390\/ijms252111395","article-title":"Exploring the chemopreventive effect of medication on gene expression linked to colorectal cancer: an observational and mendelian randomization analysis in healthy Colon Mucosa","volume":"25","author":"Moratalla-Navarro","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B90","doi-asserted-by":"publisher","first-page":"3588","DOI":"10.3390\/cancers13143588","article-title":"Repurposing DPP-4 inhibitors for colorectal cancer: a retrospective and single Center Study","volume":"13","author":"Ng","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000003760","article-title":"Gastrointestinal and hepatobiliary safety of glucagon-like Peptide-1 receptor agonists in patients with type 2 diabetes","author":"Niu","year":"2025","journal-title":"Am. J. Gastroenterol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1038\/s41598-022-06587-9","article-title":"A functional screen with metformin identifies microRNAs that regulate metabolism in colorectal cancer cells","volume":"12","author":"Orang","year":"2022","journal-title":"Sci. Rep."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.3349\/ymj.2016.57.6.1494","article-title":"Troglitazone enhances the apoptotic response of DLD-1 Colon cancer cells to photodynamic therapy","volume":"57","author":"Park","year":"2016","journal-title":"Yonsei Med. J."},{"key":"B94","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s40264-019-00892-5","article-title":"The use of long-acting insulin analogs and the risk of colorectal cancer among patients with type 2 diabetes: a population-based cohort Study","volume":"43","author":"Pradhan","year":"2020","journal-title":"Drug Saf."},{"key":"B95","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1055\/s-0034-1398564","article-title":"Glargine promotes human colorectal cancer cell proliferation via upregulation of miR-95","volume":"47","author":"Qin","year":"2015","journal-title":"Horm. Metab. Res."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.3390\/medicina61061021","article-title":"Metformin: a dual-role player in cancer treatment and prevention: a comprehensive systematic review and meta-analysis","volume":"61","author":"Rangraze","year":"2025","journal-title":"Med. (Kaunas)"},{"key":"B97","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1186\/s12876-024-03477-4","article-title":"Effect of diabetes mellitus type 2 and sulfonylurea on colorectal cancer development: a case-control study","volume":"24","author":"Rezazadeh","year":"2024","journal-title":"BMC Gastroenterol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"4012","DOI":"10.1111\/cas.14615","article-title":"Metformin changes the immune microenvironment of colorectal cancer in patients with type 2 diabetes mellitus","volume":"111","author":"Saito","year":"2020","journal-title":"Cancer Sci."},{"key":"B99","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1158\/2767-9764.CRC-21-0042","article-title":"Dipeptidyl peptidase (DPP)-4 inhibitor impairs the outcomes of patients with type 2 diabetes mellitus after curative resection for colorectal cancer","volume":"1","author":"Saito","year":"2021","journal-title":"Cancer Res. Commun."},{"key":"B100","doi-asserted-by":"publisher","first-page":"e1179","DOI":"10.1002\/ctm2.1179","article-title":"Phosphoproteomic analysis of metformin signaling in colorectal cancer cells elucidates mechanism of action and potential therapeutic opportunities","volume":"13","author":"Salovska","year":"2023","journal-title":"Clin. Transl. Med."},{"key":"B101","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/s12885-024-11985-5","article-title":"PPARG activation promotes the proliferation of colorectal cancer cell lines and enhances the antiproliferative effect of 5-fluorouracil","volume":"24","author":"Sch\u00f6ckel","year":"2024","journal-title":"BMC Cancer"},{"key":"B102","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13287-025-04174-z","article-title":"Metformin exerted tumoricidal effects on colon cancer tumoroids via the regulation of autophagy pathway","volume":"16","author":"Shabkhizan","year":"2025","journal-title":"Stem Cell Res. Ther."},{"key":"B103","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/joim.13590","article-title":"Low-dose aspirin does not lower the risk of colorectal cancer in patients with type 2 diabetes taking metformin","volume":"293","author":"Shami","year":"2023","journal-title":"J. Intern Med."},{"key":"B104","doi-asserted-by":"publisher","first-page":"609","DOI":"10.3390\/ijms25010609","article-title":"Preclinical repurposing of sitagliptin as a drug candidate for colorectal cancer by targeting CD24\/CTNNB1\/SOX4-Centered signaling hub","volume":"25","author":"Shih","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B105","doi-asserted-by":"publisher","first-page":"101658","DOI":"10.1016\/j.canep.2019.101658","article-title":"Anti-diabetic medications and the risk for colorectal cancer: a population-based nested case-control study","volume":"64","author":"Shin","year":"2020","journal-title":"Cancer Epidemiol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3322\/caac.21772","article-title":"Colorectal cancer statistics 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"B107","doi-asserted-by":"publisher","first-page":"4454","DOI":"10.1111\/dom.16489","article-title":"GLP-1 receptor agonists and the risk for cancer: a meta-analysis of randomized controlled trials","volume":"27","author":"Silverii","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"B108","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1158\/1055-9965.EPI-13-0429","article-title":"Antidiabetic medications and the risk of colorectal cancer in patients with diabetes mellitus: a systematic review and meta-analysis","volume":"22","author":"Singh","year":"2013","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"B109","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1634\/theoncologist.2011-0462","article-title":"Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis","volume":"17","author":"Soranna","year":"2012","journal-title":"Oncologist"},{"key":"B110","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s12032-022-01722-y","article-title":"Metformin inhibits the development and metastasis of colorectal cancer","volume":"39","author":"Sugiura","year":"2022","journal-title":"Med. Oncol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1185\/03007995.2013.858622","article-title":"Insulin therapy and risk of colorectal cancer: an updated meta-analysis of epidemiological studies","volume":"30","author":"Sun","year":"2014","journal-title":"Curr. Med. Res. Opin."},{"key":"B112","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1080\/1120009X.2022.2091122","article-title":"Combination of mTOR inhibitor PP242 and AMPK activator metformin exerts enhanced inhibitory effects on colorectal carcinoma cells in vitro by blocking multiple kinase pathways","volume":"35","author":"Sun","year":"2023","journal-title":"J. Chemother."},{"key":"B113","doi-asserted-by":"publisher","first-page":"e3784","DOI":"10.1002\/dmrr.3784","article-title":"Comparison between sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase 4 inhibitors on the risk of incident cancer in patients with diabetes mellitus: a real-world evidence study","volume":"40","author":"Sung","year":"2024","journal-title":"Diabetes Metab. Res. Rev."},{"key":"B114","doi-asserted-by":"publisher","first-page":"101585","DOI":"10.1016\/j.diabet.2024.101585","article-title":"Association of SGLT2 inhibitors with incident cancer","volume":"50","author":"Suzuki","year":"2024","journal-title":"Diabetes Metab."},{"key":"B115","doi-asserted-by":"publisher","first-page":"12374","DOI":"10.1038\/s41598-022-16677-3","article-title":"The effect of metformin on the survival of colorectal cancer patients with type 2 diabetes mellitus","volume":"12","author":"Tarhini","year":"2022","journal-title":"Sci. Rep."},{"key":"B116","doi-asserted-by":"publisher","first-page":"901559","DOI":"10.3389\/fphar.2022.901559","article-title":"Effects of GLP-1 receptor agonists on biological behavior of colorectal cancer cells by regulating PI3K\/AKT\/mTOR signaling pathway","volume":"13","author":"Tong","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B117","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.2337\/dc15-0563","article-title":"Use of an \u03b1-Glucosidase inhibitor and the risk of colorectal cancer in patients with diabetes: a nationwide, population-based cohort study","volume":"38","author":"Tseng","year":"2015","journal-title":"Diabetes Care"},{"key":"B118","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1002\/iub.2454","article-title":"The mechanism of sitagliptin inhibition of colorectal cancer cell lines' metastatic functionalities","volume":"73","author":"Varela-Calvi\u00f1o","year":"2021","journal-title":"IUBMB Life"},{"key":"B119","doi-asserted-by":"publisher","first-page":"8401","DOI":"10.1038\/s41598-023-34690-y","article-title":"Association between visceral obesity, metformin use, and recurrence risk in early-stage colorectal cancer","volume":"13","author":"Vedire","year":"2023","journal-title":"Sci. Rep."},{"key":"B120","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1080\/07435800.2021.1955255","article-title":"Differential risk of cancer associated with glucagon-like Peptide-1 receptor agonists: analysis of real-world databases","volume":"47","author":"Wang","year":"2022","journal-title":"Endocr. Res."},{"key":"B121","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/CAD.0000000000001254","article-title":"Effect of metformin use on the risk and prognosis of colorectal cancer in diabetes mellitus: a meta-analysis","volume":"33","author":"Wang","year":"2022","journal-title":"Anticancer Drugs"},{"key":"B122","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/1746-1596-8-180","article-title":"Insulin therapy contributes to the increased risk of colorectal cancer in diabetes patients: a meta-analysis","volume":"8","author":"Wang","year":"2013","journal-title":"Diagn Pathol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"134","DOI":"10.4093\/dmj.2022.0383","article-title":"Association of measures of glucose metabolism with colorectal cancer risk in older Chinese: a 13-Year Follow-up of the Guangzhou Biobank Cohort study-cardiovascular disease substudy and meta-analysis","volume":"48","author":"Wang","year":"2024","journal-title":"Diabetes Metab. J."},{"key":"B124","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s10020-025-01206-5","article-title":"Metformin reverses 5-FU resistance induced by radiotherapy through mediating folate metabolism in colorectal cancer","volume":"31","author":"Wang","year":"2025","journal-title":"Mol. Med."},{"key":"B125","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1080\/07435800.2017.1292525","article-title":"Exendin-4 does not modify growth or apoptosis of human colon cancer cells","volume":"42","author":"Wenjing","year":"2017","journal-title":"Endocr. Res."},{"key":"B126","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41598-024-84294-3","article-title":"Alpha-glucosidase inhibitor decreases the risk of colorectal adenoma in the aged with type 2 diabetes","volume":"15","author":"Xia","year":"2025","journal-title":"Sci. Rep."},{"key":"B127","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41419-022-04649-4","article-title":"Metformin suppresses the growth of colorectal cancer by targeting INHBA to inhibit TGF-\u03b2\/PI3K\/AKT signaling transduction","volume":"13","author":"Xiao","year":"2022","journal-title":"Cell Death Dis."},{"key":"B128","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1002\/jcb.30437","article-title":"PPAR\u03b3 agonist inhibits c-Myc-mediated colorectal cancer tumor immune escape","volume":"124","author":"Xu","year":"2023","journal-title":"J. Cell Biochem."},{"key":"B129","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1053\/j.gastro.2004.07.011","article-title":"Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients","volume":"127","author":"Yang","year":"2004","journal-title":"Gastroenterology"},{"key":"B130","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1002\/ijc.21018","article-title":"Peroxisome proliferator-activated receptor gamma agonist troglitazone induces colon tumors in normal C57BL\/6J mice and enhances colonic carcinogenesis in Apc1638 N\/+ Mlh1+\/- double mutant mice","volume":"116","author":"Yang","year":"2005","journal-title":"Int. J. Cancer"},{"key":"B131","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1007\/s00384-020-03704-w","article-title":"Relationship between metformin therapy and risk of colorectal cancer in patients with diabetes mellitus: a meta-analysis","volume":"35","author":"Yang","year":"2020","journal-title":"Int. J. Colorectal Dis."},{"key":"B132","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/1746-1596-9-91","article-title":"Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients: a systemic review and meta-analysis","volume":"9","author":"Yin","year":"2014","journal-title":"Diagn Pathol."},{"key":"B133","doi-asserted-by":"publisher","first-page":"4713","DOI":"10.1038\/s41598-020-61661-4","article-title":"Cell cycle synchronisation using thiazolidinediones affects cellular glucose metabolism and enhances the therapeutic effect of 2-deoxyglucose in colon cancer","volume":"10","author":"Yoon","year":"2020","journal-title":"Sci. Rep."},{"key":"B134","doi-asserted-by":"publisher","first-page":"676","DOI":"10.3892\/or.2015.4429","article-title":"The dipeptidyl peptidase-4 inhibitor sitagliptin suppresses mouse colon tumorigenesis in type 2 diabetic mice","volume":"35","author":"Yorifuji","year":"2016","journal-title":"Oncol. Rep."},{"key":"B135","first-page":"631","article-title":"Thiazolidinedione, a peroxisome proliferator-activated receptor-gamma ligand, inhibits growth and metastasis of HT-29 human colon cancer cells through differentiation-promoting effects","volume":"25","author":"Yoshizumi","year":"2004","journal-title":"Int. J. Oncol."},{"key":"B136","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.3748\/wjg.v13.i10.1534","article-title":"Rosiglitazone enhances fluorouracil-induced apoptosis of HT-29 cells by activating peroxisome proliferator-activated receptor gamma","volume":"13","author":"Zhang","year":"2007","journal-title":"World J. Gastroenterol."},{"key":"B137","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.3390\/molecules26071990","article-title":"Metformin inhibits the urea cycle and reduces putrescine generation in colorectal cancer cell lines","volume":"26","author":"Zhang","year":"","journal-title":"Molecules"},{"key":"B138","doi-asserted-by":"publisher","first-page":"4633","DOI":"10.2147\/DDDT.S336490","article-title":"The effect of metformin on the proliferation, apoptosis and CD133 mRNA expression of Colon cancer stem cells by upregulation of miR 342-3p","volume":"15","author":"Zhang","year":"","journal-title":"Drug Des. Devel Ther."},{"key":"B139","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1007\/s00384-022-04212-9","article-title":"Metformin use is not associated with colorectal cancer incidence in type-2 diabetes patients: evidence from methods that avoid immortal time bias","volume":"37","author":"Zhang","year":"2022","journal-title":"Int. J. Colorectal Dis."},{"key":"B140","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1186\/s12876-025-04211-4","article-title":"Association between GLP-1 receptor agonists as a class and colorectal cancer risk: a meta-analysis of retrospective cohort studies","volume":"25","author":"Zhong","year":"2025","journal-title":"BMC Gastroenterol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1849647\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:53:19Z","timestamp":1781671999000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1849647\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":140,"alternative-id":["10.3389\/fphar.2026.1849647"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1849647","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"article-number":"1849647"}}